Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Press release

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

Graphic

Revenue increased 35% compared to prior year

Raises low end of 2026 revenue outlook

BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026.

"We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founder. "Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape. NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue. With continued operational discipline and healthy customer funding supporting demand, we are well positioned as we head toward the end of the year.”

Recent Highlights

  • Revenue of $19.0 million for the third quarter of 2026, increasing 35% year-over-year
  • Recurring revenue of $5.1 million, representing 27% of total revenues for the quarter
  • Gross margin of 53% and adjusted gross margin of 58% for the third quarter of 2026
  • Net loss from continuing operations of $4.6 million and Adjusted EBITDA loss of $1.7 million for the third quarter of 2026
  • Ended the quarter with a strong balance sheet, with a cash position of $99.1 million
  • Shipped approximately 100 NIRLab devices in the first full quarter following the acquisition

Third Quarter 2026 Financial Results

Revenue was $19.0 million for the three months ended September 30, 2026, a 35% increase over the prior year period, driven by an increase in product revenue for FTIR devices and the addition of NIRLab revenue. The installed base grew 26% year-over-year to 4,409 devices, with 308 devices placed during the third quarter, a new company record. Recurring revenue represented 27% of total revenues in the quarter.

Gross profit was $10.0 million for the third quarter of 2026, compared to $7.4 million for the corresponding period in the prior year. GAAP gross margin was 53% as compared to 53% for the corresponding prior year period. Adjusted gross profit was $10.9 million for the third quarter of 2026, compared to $8.1 million for the corresponding period in the prior year. Adjusted gross margin was 58%, as compared to 58% for the corresponding prior year period.

Operating expenses were $15.5 million for the third quarter of 2026, compared to $23.7 million for the corresponding prior year period. The $8.2 million decrease was primarily driven by an $11.0 million noncash reduction in expense related to the change in fair value of contingent consideration, partially offset by a $2.8 million increase in selling, general and administrative expenses.

Net loss from continuing operations was $4.6 million for the third quarter of 2026, compared to a net loss from continuing operations of $14.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.7 million for the third quarter of 2026, compared to a loss of $1.8 million for the corresponding period in the prior year.

Net loss attributable to common stockholders was $4.6 million for the third quarter of 2026, compared to $15.0 million for the corresponding prior year period.

Cash, cash equivalents and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.

2026 Guidance

908 Devices updates its full year revenue guidance range to $68.5 million to $70.0 million (from $68.0 million to $70.0 million previously), raising the low end of the range and representing 22% to 25% growth compared to 2025 revenue.

Webcast Information

908 Devices will host a conference call to discuss the third quarter 2026 financial results before market open on Tuesday, November 10, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Non-GAAP Measures of Financial Performance

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

  • Adjusted gross profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation.
  • Adjusted gross margin is defined as adjusted gross profit expressed as a percentage of total revenue.
  • Adjusted EBITDA is defined as net income (loss) from continuing operations excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company’s acquisitions and for which the conditions for payment have not yet been achieved.

The Company has not reconciled its guidance for adjusted gross margin and adjusted EBITDA to GAAP gross margin and GAAP net loss from continuing operations, respectively, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, because certain reconciling items that affect these measures, including changes in the fair value of contingent consideration related to the NIRLAB acquisition, acquisition and integration related costs, and income tax effects, have not occurred, are outside the Company’s control, or cannot be reasonably predicted. Accordingly, reconciliations to the most directly comparable GAAP measures are not available without unreasonable effort. These unavailable items could significantly affect the Company’s GAAP results.

The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.  

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and future business prospects and market opportunities. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Contact:

Matt Roache

VP, Investor Relations

mroache@908devices.com

908 DEVICES INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended September 30, 

Nine Months Ended September 30, 

2026

2025

2026

2025

Revenue:

Product revenue

$

15,758

$

10,844

$

39,469

$

28,950

Service and contract revenue

3,192

3,161

8,937

9,867

Total revenue

18,950

14,005

48,406

38,817

Cost of revenue:

Product cost of revenue

7,594

5,290

19,167

15,338

Service and contract cost of revenue

1,339

1,360

3,997

4,210

Total cost of revenue

8,933

6,650

23,164

19,548

Gross profit

10,017

7,355

25,242

19,269

Operating expenses:

Research and development

3,819

3,837

10,888

12,071

Selling, general and administrative

11,980

9,134

33,007

29,712

Change in fair value of contingent consideration

(305)

10,708

12,518

19,999

Total operating expenses

15,494

23,679

56,413

61,782

Loss from operations

(5,477)

(16,324)

(31,171)

(42,513)

Other income, net

1,443

2,639

4,958

Loss from continuing operations before income taxes

(4,629)

(14,881)

(28,532)

(37,555)

Income tax benefit (expense), net

(29)

(100)

Net loss from continuing operations

(4,579)

(14,910)

(28,428)

(37,655)

Net income (loss) from discontinued operations, net of tax

—

(72)

—

52,970

Net income (loss) attributable to common stockholders

$

(4,579)

$

(14,982)

$

(28,428)

$

15,315

Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted

$

(0.11)

$

(0.41)

$

(0.74)

$

(1.05)

Net income (loss) from discontinued operations per share attributable to common stockholders, basic and diluted

$

—

$

—

$

—

$

1.48

Net income (loss) per share attributable to common stockholders, basic and diluted

$

(0.11)

$

(0.41)

$

(0.74)

$

0.43

Weighted average common shares outstanding

Basic and diluted

41,069,053

36,101,051

38,554,027

35,791,111

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

September 30, 

December 31, 

2026

2025

Assets

Current assets:

Cash, cash equivalents and marketable securities

$

99,122

$

112,970

Accounts receivable, net

17,219

11,327

Inventory

14,693

12,990

Prepaid expenses and other current assets

4,111

7,272

Total current assets

135,145

144,559

Operating lease, right-of-use assets

4,729

4,397

Property and equipment, net

4,440

4,232

Goodwill

10,244

—

Intangible, net

44,066

36,412

Other long-term assets

Total assets

$

199,358

$

190,071

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses

$

11,005

$

8,424

Deferred revenue

11,592

8,934

Operating lease liabilities and other liabilities

2,290

16,706

Total current liabilities

24,887

34,064

Deferred revenue, net of current portion

11,291

8,331

Contingent consideration, net of current portion

8,189

—

Other long-term liabilities

5,188

3,977

Total liabilities

49,555

46,372

Total stockholders' equity

149,803

143,699

Total liabilities and stockholders' equity

$

199,358

$

190,071

908 DEVICES INC.

Reconciliations of GAAP to Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except percentage and per share data)

In all tables below, totals may not add due to rounding

Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2026

2025

2026

2025

Gross Profit (GAAP)

$

10,017

7,355

25,242

19,269

Intangible amortization

2,154

1,904

Acquisition and integration costs

-

-

-

Restructuring

-

Stock-based compensation

Adjusted Gross Profit (Non-GAAP)

$

10,947

$

8,148

$

27,802

$

21,892

Gross Margin Percentage (GAAP)

53%

53%

52%

50%

Adjusted Gross Margin Percentage (Non-GAAP)

58%

58%

57%

56%

Reconciliation from Net Income (Loss) from Continuing Operations (GAAP) to Adjusted EBITDA (Non-GAAP):

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2026

2025

2026

2025

Net Loss from continuing operation (GAAP)

$

(4,579)

(14,910)

(28,428)

(37,655)

Adjustments:

Other income, net

(848)

(1,443)

(2,639)

(4,958)

Benefit (Provision) for income taxes

(50)

(104)

Depreciation

1,333

Intangible amortization

1,019

2,680

2,158

Acquisition and integration costs

1,196

Restructuring

1,507

Stock-based compensation

2,337

2,379

7,049

6,935

Change in fair value of NIRLAB holdback shares

-

-

Change in fair value of contingent consideration

(305)

10,708

12,518

19,999

Adjusted EBITDA (Non-GAAP)

$

(1,677)

$

(1,842)

$

(6,129)

$

(10,302)

Source: 908 Devices Inc.. This release was filed with the U.S. Securities and Exchange Commission on Nov 10, 2026 and is reproduced here as issued. View the filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.